Clinical trial registry record

A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 8, 2015.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00484939
Last registry update
January 8, 2015
Status
Completed
Phase
Phase 3
Sponsor
Hoffmann-La Roche
Enrollment
280
Countries
Austria, Canada, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Slovenia, South Korea, Spain, United Kingdom
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
280
Population
ALL · 70 Years
Duration
2007-07-01 to 2013-03-01
Intervention
Bevacizumab; Capecitabine
Comparator
Capecitabine
Outcomes measured
Progression-free Survival — Baseline to the end of the study (up to 5 years 8 months); Best Overall Response (BOR) — Baseline to the end of the study (up to 5 years 8 months); Duration of Response — Baseline to the end of the study (up to 5 years 8 months); Time to Response — Baseline to the end of the study (up to 5 years 8 months); Overall Survival — Baseline to the end of the study (up to 5 years 8 months); Eastern Cooperative Oncology Group (ECOG) Performance Status — Baseline to the Safety Follow-up which occurred 28 days…; Percentage of Participants Requiring Additional Treatment for Malignancy — Baseline to the end of the study (up to 5 ye…; Duration of Follow-up — Baseline to the end of the study (up to 5 years 8 months); AEs, Laboratory Parameters, Vital Signs — Throughout study
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON